Embecta Corp. (EMBC)

NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23

$6.71-2.19%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Embecta Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2027 · Q1
Revenue	—	265.02M
EPS	—	0.493
FY 2026 · Annual
EPS	$1.8–$1.9non-GAAP	—
Operating margin	23.5%–24%non-GAAP	—
FY 2027 · Annual
Revenue	—	1.07B
EPS	—	1.763
FY 2028 · Annual
Revenue	—	1.09B
EPS	—	1.951

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Complete $100M share repurchase program and maintain low dividend	The dividend cut to $0.01 per share boosts financial flexibility.	Intact	Dividend rises above $0.05 or buyback program stalls	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful integration of Owen Mumford acquisition	Embecta completed the acquisition of Owen Mumford to expand its product range.	Improving	Acquisition integration delays or failure to realize synergies	Integration completed 2026-05-15; Q2 2026 earnings beat Owen Mumford acquisition completed May 15, 2026. Q2 2026 earnings beat. Q1 2026 miss and S&P credit cut noted. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating margin near 22.75% next quarter	The company targets about $1.025 billion revenue and 22.75% profit margin next quarter.	Under Pressure	Operating margin falls below 20% next quarter	Operating margin: 17.92% FY2026-Q3; GAAP. Published target: ~22.75%. Target period ends 2026-09-30; this observation covers 2026-Q3. Source published Aug 7, 202617.924181 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 45255060-604b-4d75-a992-3e1a495d09b7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches about $1.025 billion next quarter	The company targets about $1.025 billion revenue and 22.75% profit margin next quarter.	Broken	Revenue falls below $1.0 billion next quarter	Revenue: $271.7M FY2026-Q3; GAAP. Published target: ~$1.025 billion. Target period ends 2026-09-30; this observation covers 2026-Q3. Source published Aug 7, 2026271,700,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q3 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 45255060-604b-4d75-a992-3e1a495d09b7. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2028 · fiscal year ending 2028-09-30 · fmp

FY2028 EPS: comparable history unavailable.

FY2028 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2028 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	1	3	1
2026-06-01	1	3	1
2026-07-01	0	3	1
2026-08-01	0	3	1
2026-09-01	0	3	1
2026-10-01	0	3	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 3 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Complete $100M share repurchase program and maintain low dividendDirect metric needs a verified mapping
Operating margin near 22.75% next quarterPublished status: Under Pressure
Revenue reaches about $1.025 billion next quarterPublished status: Broken

Next proof point

Nov 24, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-79.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Embecta Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a smaller-cap healthcare business with a value-oriented setup, rather than a proven, steady compounder. The long-term thesis is intact, but earnings quality is fragile and the evidence behind that view has medium confidence.

What's priced into Embecta Corp.

EMBC is described as cheap versus peers, while the valuation model has low confidence. The pricing evidence calls the setup justified and shows low fragility, so it does not point to a market assumption of a fully expensive, weak, and turbulent business.

What the fundamentals likely do

Near-term results have been strong overall, though recent earnings have been erratic, with a miss in May followed by a beat and a guidance raise in August. Management is progressing on the Owen Mumford integration, product launches, and debt reduction; near-term risks include a reversal in guidance and weaker employment conditions.

What Embecta Corp. hinges on

Over the next one to three years, the thesis hinges on maintaining guidance credibility and turning the acquisition and product launches into sustained business progress. Continued strength from healthcare peers could support the sector backdrop, while weakening jobs data could increase pressure on cyclical healthcare names.

Bottom line

The 1-3 year view remains intact, supported by recent performance and management execution, but fragile earnings quality and elevated risk make delivery the key test. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.